Carmustine, Implant
Recommended · restricted OncologyRestricted benefitLater-line line
Newly-diagnosed glioblastoma multiforme as an adjunct to surgery and radiation.
1
Submissions
2005–05
On the record
—
ICER range
Cost-min
Cost basis
Access path
- Nov 2005Recommended · restricted
vs temozolomide
- PBS listing · Restricted benefit
RecommendedDeferredNot recommended
Cost-effectiveness
Cost-minimisation basis: carmustine implant listed as equivalent to temozolomide course. Numeric ICER not calculated for the comparison; trial-based incremental costs provided but PBAC recommended cost-minimisation approach.
The PBAC concluded that, overall, carmustine implants are no worse than temozolomide for glioblastoma multiforme, the main indication within the requested restriction. PBAC · 2005
Cost-effectiveness accepted
Decision context
PopulationNewly-diagnosed glioblastoma multiforme patients as an adjunct to surgery and radiation.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2005 | Recommended · restricted | temozolomide | — | RCT · OS, Q-TWiST |
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC restricted to newly-diagnosed GBM only; TGA label also includes recurrent GBM patients.